Rafael (RFL) AVENGER 500 Phase 3 clinical trial evaluating CPI-613 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients misses primary endpoint
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
Go back to Rafael (RFL) AVENGER 500 Phase 3 clinical trial evaluating CPI-613 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients misses primary endpoint
October 28, 2021 8:00 AM EDT
CRANBURY, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a company focused on the growing field of cancer metabolism-based therapeutics, today announced that the AVENGER 500 Phase 3 clinical trial evaluating the efficacy and safety of CPI-613® (devimistat) in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients with metastatic adenocarcinoma of the pancreas did not meet its primary endpoint of overall survival.
In this multi-national... More